Completed PHASE2 INTERVENTIONAL 3-arm NCT01780584

Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?

Oral Triiodothyronine Normalizes T3 Levels After Surgery For Pediatric Congenital Heart Disease

Sponsor: National Cardiovascular Center Harapan Kita Hospital Indonesia

Interventions Oral T3 Low dose Oral T3 high dose Placebo

Updated 6 times since 2017 Last updated: Feb 2, 2013 Started: Apr 30, 2010 Primary completion: Sep 30, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Low T3 Syndrome and is currently completed. National Cardiovascular Center Harapan Kita Hospital Indonesia leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cardiovascular Center Harapan Kita Hospital Indonesia

Data source: National Cardiovascular Center Harapan Kita Hospital Indonesia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jakarta, Indonesia